Urachal carcinoma: surgical and chemotherapeutic options

References

• Sheldon CA, Clayman RV, Gonzalez R et al. Malignant urachal lesions. J. Urol.131, 1–8 (1984).
   PubMed Web of Science ®Google Scholar
• Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology42, 635–639 (1993).
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Gee J, Shen Y et al. Multimodality management of urachal carcinoma. The M. D. Anderson Cancer Center experience. J. Urol.169, 1295–1298 (2003).
   PubMed Web of Science ®Google Scholar
• Wright JL, Porter MP, Li CI et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer107, 721–728 (2006).
   PubMed Web of Science ®Google Scholar
• Ashley RA, Inman BA, Sebo TJ et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer107, 712–720 (2006).
   PubMed Web of Science ®Google Scholar
• Schubert GE, Pavkovic MB, Bethke-Bedurftig BA. Tubular urachal remnants in adult bladders. J. Urol.127, 40–42 (1982).
   Google Scholar
• Begg RC. The urachus: anatomy, histology, and development. J. Anat.64, 170 (1930).
   PubMedGoogle Scholar
• Hammond G, Yglesias L, Davis J. Urachus, its anatomy and associated fasciae. Anat. Rec.80, 271 (1941).
   Google Scholar
• Johnson DE, Hodge GB, Abdul-Karim FW et al. Urachal carcinoma. Urology26, 218–221 (1985).
   PubMed Web of Science ®Google Scholar
• Grignon DJ, Ro JY, Ayala AG et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer67, 2165–2172, (1991).
   PubMed Web of Science ®Google Scholar
• Shaw JL, Gislason GJ, Imbriglia JE. Transition of cystitis glandularis to primary adenocarcinoma of the bladder. J. Urol.79, 815 (1958).
   Google Scholar
• Wheeler J, Hill WT. Adenocarcinoma involving the urinary bladder. Cancer7, 119 (1954).
   PubMed Web of Science ®Google Scholar
• Mostofi FK, Thomson RV, Dean ALJ. Mucous adenocarcinoma of the urinary bladder. Cancer8, 741–758 (1955).
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Czerniak BA, Dinney CP, Millikan RE. Uncommon cancers of the bladder. In: Textbook of Uncommon Cancer, Third Edition. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG (Eds). John Wiley & Sons, NJ, USA 18–26 (2006).
   Google Scholar
• Takeuchi M, Matsuzaki K, Yoshida S et al. Imaging findings of urachal mucinous cystadenocarcinoma associated with pseudomyxoma peritonei. Acta Radiologica45, 348–350 (2004).
   Web of Science ®Google Scholar
• Kikuno N, Urakami S, Shigeno K et al. Urachal carcinoma associated with increased carbohydrate antigen 19–9 and carcinoembryonic antigen. J. Urol.166, 604 (2001).
   Google Scholar
• Guarnaccia S. Adenocarcinoma of the urachus associated with elevated levels of CA 125. J. Urol.145, 140–141 (1991).
   Google Scholar
• Milhoua PM, Knoll A, Bleustein CB et al. Laparoscopic partial cystectomy for treatment of adenocarcinoma of the urachus. Urology67(2), 423.E15–423.E17 (2006).
   Google Scholar
• Wadhwa P, Kolla SB, Hemal AK. Laparoscopic en bloc partial cystectomy with bilateral pelvic lymphadenectomy for urachal adenocarcinoma. Urology67, 837–843, (2006).
   PubMed Web of Science ®Google Scholar
• Madeb R, Knopf JK, Nicholson C et al. The use of robotically assisted surgery for treating urachal anomalies Br. J. Urol. Int.98, 838–842 (2006).
   Google Scholar
• Herr HW. Urachal carcinoma: the case for extended partial cystectomy. J. Urol.151, 365–356 (1994).
   PubMed Web of Science ®Google Scholar
• Pinthus JH, Haddad R, Trachtenberg J et al. Population based survival data on urachal tumors. J. Urol.175, 2042–2047 (2006).
   PubMed Web of Science ®Google Scholar
• Lane V. Prognosis in carcinoma of the urachus. Eur. Urol.2, 282–283 (1976).
   Google Scholar
• Kakizoe T. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology21, 360–366 (1983).
   Google Scholar
• Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology26, 252–255 (1985).
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Millikan RE, Tu SM et al. Phase III trial of fluorouracil, interferon α-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J. Clin. Oncol.20, 1361–1367 (2002).
   PubMed Web of Science ®Google Scholar
• Kojima Y, Yamada Y, Kamisawa H et al. Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int. J. Urol.13, 1123–1125 (2006).
   Web of Science ®Google Scholar
• Kume H, Tomita K, Takahashi S et al. Irinotecan as a new agent for urachal cancer. Urol. Int.76, 281–282 (2006).
   Web of Science ®Google Scholar
• Galsky MD, Iasonos A, Mironov S et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell carcinomas of the urothelial tract. 24(Suppl. 18), 4542J. Clin. Oncol. (2006).
   Google Scholar